They're not dredging up algae and feeding it to lab mice. At least, not yet.
So far, the scientists have just done lab tests on a compound made by cyanobacteria -- commonly called "blue-green algae" -- and they like what they've seen. Cyanobacteria are not true algae, but bacterial organisms which live in the water and have photosynthetic properties like plants.
Paul Becher of the University of Zurich and colleagues report the findings in the Journal of Natural Products.
Don't get the wrong idea from the journal's name. This study isn't about a product that's on the market. It could be years before anyone knows if this early research will actually help anyone facing Alzheimer's.
Still, pond scum's image is looking up -- for the moment, anyway.
Talk about humble beginnings. The compound studied by Becher's team originally came from cyanobacteria in a wastewater lagoon. It was then frozen, dried, and purified.
Next, the scientists used lasers and chemicals to analyze the compound, which is called nostocarboline.
Then came the big test. The researchers exposed nostocarboline to a type of enzyme called cholinesterase. The algae compound thwarted cholinesterase.
Working against the action of cholinesterase can help with acetylcholine levels. Some current Alzheimer's drugs (such as Aricept, Exelon, and Razadyne) target cholinesterase in a similar fashion. The researchers compared the strength of cholinesterase-inhibiting activity of nostocarboline with that of Razadyne and found it to be similar.
Nostocarboline might one day lead to new drugs that counter brain diseases, the researchers write.